 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- FHD-609 / Foghorn Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: FHD-609-C-001: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors (clinicaltrials.gov) - Apr 25, 2024
P1, N=55, Terminated, Sponsor: Foghorn Therapeutics Inc.
N=104 --> 55 | Trial completion date: May 2025 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Dec 2023; Sponsor decision
- FHD-609 / Foghorn Therap
Discovery of FHD-609: A potent and selective heterobifunctional degrader of BRD9 (In-person; Room 356 (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_1818;
In preclinical studies, FHD-609 has been shown to selectively degrade bromodomain-containing protein 9 (BRD9), taking advantage of a synthetic lethal relationship with the SS18-SSX translocation. The discovery and optimization of this first-in-class clinical compound will be described.
- FHD-609 / Foghorn Therap
Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models (Section 24) - Mar 5, 2024 - Abstract #AACR2024AACR_9391;
The long acting FHD-609 injectable formulation has the potential to offer better patient compliance and acceptance in clinical settings than IV dosing. The long acting injectable formulation provides a promising and effective drug delivery option for various protein degraders that are not orally bioavailable.
- FHD-609 / Foghorn Therap
Investigation of FHD-609, a potent degrader of BRD9, in preclinical models of acute myeloid leukemia (AML). (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_209;
- || FHD-609 / Foghorn Therap
Enrollment closed, Metastases: FHD-609-C-001: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors (clinicaltrials.gov) - Apr 27, 2023
P1, N=104, Active, not recruiting, Sponsor: Foghorn Therapeutics Inc.
The long acting injectable formulation provides a promising and effective drug delivery option for various protein degraders that are not orally bioavailable. Recruiting --> Active, not recruiting
- || FHD-609 / Foghorn Therap
Enrollment change, Metastases: FHD-609-C-001: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors (clinicaltrials.gov) - Oct 4, 2022
P1, N=104, Recruiting, Sponsor: Foghorn Therapeutics Inc.
Recruiting --> Active, not recruiting N=70 --> 104
- FHD-609 / Foghorn Therap
PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA () - Sep 9, 2022 - Abstract #CTOS2022CTOS_419;
Using these methods, we found that higher doses of FHD-609 led to more prolonged suppression of BRD9 in tumors and PBMCs. Our results also suggest that certain PBMC populations are effective surrogates for tumor PD, which may enable longitudinal assessment of target engagement through serial blood collection in the clinic.
- | INO-5401 / Inovio, suratadenoturev (OBP-301) / Oncolys BioPharma, FHD-609 / Foghorn Therap
Journal: Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. (Pubmed Central) - Jun 11, 2022
We identified TP53-modulating drugs to be possibly effective in 20-26% of patients, followed by the Wnt signaling pathway inhibitors (15%), Telomelysin and INO5401 (13%), FHD-609 (13%), etc. According to our data, 67% of ACC patients exhibited genomic alterations that might be targeted by FDA-approved drugs or drugs being tested in current clinical trials. Although there are not many current therapy options directly targeting reported ACC alterations, this study identifies emerging options that could be tested in clinical trials.
- FHD-609 / Foghorn Therap
DISCOVERY OF A POTENT AND SELECTIVE BRD9 DEGRADER FHD-609 FOR THE TREATMENT OF SYNOVIAL SARCOMA AND OTHER CANCERS WITH DYSREGULATION OF CHROMATIN REMODELER COMPLEXES ([VIRTUAL]) - Nov 26, 2021 - Abstract #CTOS2021CTOS_396;
This drug candidate possesses suitable drug like properties and potently degrades BRD9, which translates into strong anti-tumor activity in synovial sarcoma cell lines. FHD-609 has a durable PD profile and shows strong efficacy as mono-agent therapy in synovial sarcoma xenograft models with an intermittent (BIW) administration and compares favorably to standard-of-cares, such as ifosfamide or pazopanib, that were tested in the same models.
- ||| FHD-609 / Foghorn Therap
New P1 trial, Metastases: FHD-609-C-001: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors (clinicaltrials.gov) - Jul 15, 2021
P1, N=70, Recruiting, Sponsor: Foghorn Therapeutics Inc.